Novartis's Gilenya Treatment Fails in Trial for Difficult Form of MS
Wall Street Journal
ZURICH- Novartis AG Monday said a late-stage study showed little difference between its top-selling Gilenya drug and a placebo for treating a difficult form of multiple sclerosis. Basel-based Novartis said the Phase III trial of the treatment, which is already ...
Novartis's Gilenya Fails to Help Hard-to-Treat Form of MSBloomberg
Novartis Says Fingolimod Phase III Trial In PPMS Fails To Meet Primary GoalNasdaq
Novartis' Gilenya fails in study for a type of MSWKZO

all 13 news articles »